ISPOR Health Economics and Outcomes Research - Application Award

Dan Greenberg

Dan Greenberg, PhD, Associate Professor and Chairman, Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Award Policies and Procedures

ISPOR Health Economics and Outcomes Research - Application Award was established in 1997 to recognize outstanding practical application of pharmacoeconomics and outcomes research in health care decision-making.

The award is given to a distinguished example of applied health outcomes research that has or is expected to have a high impact on health policy or healthcare decision making. Preference is given to papers with creative application of health outcomes research, encompassing topics such as health policy, evaluation and adoption of health technologies, and other issues that further the goals and objectives of the Society. The award is selected by the ISPOR Excellence Awards Committee from nominated papers that have appeared in print or e-pub in peer-review journals during the preceding calendar year (e-pub must be listed in Medline) and other communication venues (e.g. books, reports). Self-nominations are encouraged and accepted for consideration.

A candidate may only be nominated for one major ISPOR award in a year.

Selection Process:
A call for nominations is placed in November-December Value & Outcomes Spotlight for articles published during the past twelve months to be considered for the ISPOR Health Economics and Outcomes Research - Application Award. In addition, each Excellence Award Committee member selects relevant publications in respected peer-reviewed journals during the preceding twelve months to be considered by the Awards Committee in the selection process. The Excellence Award Committee meets via teleconference in February to discuss each of the nominated publications.  They select the best demonstration of scientific excellence for that time period.  The nominee is then forwarded to the Board of Directors for final approval. The corresponding author on the publication is given the award.

Nature of Award:
The Award, presented at the ISPOR Annual International Meeting to the corresponding author of the paper, consists of a plaque, complimentary Annual International Meeting registration, roundtrip air fare, hotel, meal and miscellaneous expenses for two days, based upon current ISPOR travel policies.

Nominations for the ISPOR Health Economics and Outcomes Research - Application Award should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and sent to Only ISPOR members may submit nominations (either their own publications or others).

Receipients of The ISPOR Health Economics and Outcomes Research - Application Award

Myerson Rebecca Myerson, MPH, PhD,
School of Pharmacy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, Los Angeles, CA, USA

For the paper, “Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York,” JAMA Cardiol 2017;2:627-634.

Rebecca Myerson, MPH, PhD, is an assistant professor at the University of Southern California and affiliate of USC’s Schaeffer Center for Health Policy and Economics. She holds a PhD in public policy with a concentration in applied econometrics from University of Chicago and an MPH from University of Washington. With the goal of informing policy to improve health, her research aims to quantify the impacts of policies on incidence and treatment of diabetes and cardiovascular disease. Her health economics research assesses whether informing patients about their health biomarkers and health insurance options closes gaps in uptake of needed care. Specific projects have analyzed trans fat restrictions, screening interventions, assistance programs for health insurance enrollment, and Medicaid eligibility expansions. Rebecca has received research funding from the Agency for Healthcare Research and Quality and a Fulbright Scholarship. Rebecca gratefully accepts this award on behalf of her coauthors, Eric Brandt, Marcelo Coca-Peraillon, and Tamar Polonsky.

Jeff Richardson, PhD Jeff Richardson, PhD,
Professor and Foundation Director, Centre for Health Economics, Monash University

For the paper, Measuring the Sensitivity and Construct Validity of 6 Utility Instruments in 7 Disease Areas,” Med Decis Making 2016;36:147–159.

Jeff Richardson, PhD, is a Professor and Foundation Director of the Centre for Health Economics at Monash University. He has held honorary positions at Stanford University, the Australian National University and the University of South Australia and worked as a consultant for the WHO, AusAID (the Australian foreign aid organization), and the Australian Government chairing a 2004 review of the Tasmanian health system. He was president of the Australian Health Economics Society for 7 years and a member of the tribunal, which determines pharmaceutical remuneration for 16 years. His research has included the earliest econometric modelling of the Australian health system and the first use of Cost Utility Analysis in Australia. This led to the development of the AQoL suite of utility instruments, the AQoL website and an ethical analysis of the QALY (a book co-authored with Peter Singer). Recent work has focused upon social preferences for health outcomes. He has 213 unrefereed research reports and 195 peer reviewed articles or book chapters.

Joshua J. Gagne, PharmD, ScD Joshua J. Gagne, PharmD, ScD,
Assistant Professor of Medicine at Harvard Medical School and a pharmacoepidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital.

For the paper, " Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data" Value Health. 2015; 18:1063-1069.

Dr. Gagne is an Assistant Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School and an Assistant Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. His research focuses on methods for generating post-approval comparative safety and effectiveness evidence for new medical products. He is Co-Lead of the Methods Core of the FDA Sentinel program. He teaches courses in pharmacoepidemiology and comparative-effectiveness research at the Harvard T.H. Chan School of Public Health, where he co-directs the Pharmacoepidemiology Program. His research is funded by AHRQ, FDA, PCORI, and the Reagan-Udall Foundation. Dr. Gagne earned his PharmD degree from the University of Rhode Island College of Pharmacy and his ScD degree in Epidemiology from the Harvard T.H. Chan School of Public Health. He serves on the editorial boards of Drug Safety and Pharmacoepidemiology and Drug Safety.

Joshua A. Roth, PhD, MHA Joshua A. Roth, PhD, MHA
Assistant Member, AHRQ Patient-Centered Outcomes Research K12 Scholar, Hutchinson Institute for Cancer Outcomes Research (HICOR), Fred Hutch, Seattle, WA, USA

For the paper, "Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study" Ann Intern Med. 2014;160:594-602.

Dr. Roth is an Assistant Member at the Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson Cancer Research Center, and an Affiliate Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. Additionally, he is currently an Agency for Healthcare Research and Quality K12 scholar in patient-centered outcomes research. Dr. Roth's primary research interest is application of comparative effectiveness research methods to inform translation of lung and breast cancer therapeutics and diagnostics, including: observational study design, decision modeling, randomized controlled trial design, systematic review, and meta-analysis. His current research focuses on evaluating patient perspectives on lung cancer screening, and applying value of information analysis to identify high-value study designs for future lung cancer screening research. Dr. Roth received his PhD in pharmaceutical outcomes research from the University of Washington. He also holds a MHA degree from the department of health services at the University of Washington.

Marisa Elena Domino, PhD Marta O. Soares, Researcher,Centre for Health Economics, University of York

For the paper, Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse: Negative-Pressure Wound Therapy for Severe Pressure Ulcers” Med Decis Making 2013 33: 415.

Marta O. Soares, is a Researcher in the Centre for Health Economics at the University of York ( She holds an MSc in Biostatistics awarded by the University of Lisbon in 2008. Marta is currently a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee.
Marta has worked on a variety of applied projects, in clinical areas including wound care, epilepsy and sepsis. She has carried out a range of methods research in areas including expert elicitation, evidence synthesis, decision modeling and value of information analysis. Marta has also been involved in policy-focused methods development including a framework to support decision making in the face of different types of evidential uncertainty and estimation of the NICE cost-effectiveness threshold.

Marisa Elena Domino, PhD Marisa Elena Domino, PhD, Professor, Health Policy and Management, the University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA

For the paper, “Does Managed Care Affect the Diffusion of Psychotropic Medications?” Health Econ. 2012 Apr; 21(4):428-43.

Marisa Elena Domino, PhD, is a Professor in the Department of Health Policy and Management in the Gillings School for Global Public Health at the University of North Carolina at Chapel Hill. She received her PhD in Health Economics from the Johns Hopkins University and completed a Postdoctoral Fellowship in the economics of mental health at Harvard Medical School’s Department of Health Care Policy. Dr. Domino’s research interests include the economics of mental health, agency relationships among physicians, patients and insurers, the diffusion of new technologies, and the public provision of health care and health insurance to low income populations. Dr. Domino completed a K01 Career Development Award from the National Institute of Mental Health to analyze factors that affect the diffusion of psychotropic medications in a variety of populations. She has worked on a variety of projects on insurance design, behavioral health, and chronic illness including papers on the use of medical homes in specialty care populations, behavioral health carve-outs, and assertive community treatment.

Ties Hoomans PhD, MSc Niteesh K. Choudhry, MD, PhD, Associate Professor, Harvard Medical School, Boston, MA, USA

For the paper, “Full Coverage for Preventive Medications after Myocardial Infarction” N Engl J Med 2011;365:2088-97.

Niteesh K. Choudhry, MD, PhD, is an internist and health services researcher whose work focuses on the clinical and economic consequences of evidence-based therapies for the management of common chronic conditions. He is particularly interested in the design and evaluation of novel strategies to overcome barriers to treatment initiation and long-term medication adherence. His work employs a broad range of methods including randomized policy evaluations, cost-effectiveness modeling, claims analyses, and surveys. Dr. Choudhry is an Associate Professor at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital.  He received his MD and completed his residency training in Internal Medicine at the University of Toronto, did his PhD in Health Policy at Harvard University and was a Fellow in Pharmaceutical Policy Research at Harvard Medical School. He practices inpatient general internal/hospital medicine and is actively involved in resident education.

Craig J. Currie Craig J. Currie, PhD
Reader in Diabetes Pharmacoepidemiology, Department of Primary Care and Public Health, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre, University Hospital of Wales, Cardiff, UK

For the paper, Currie, CJ, Peters, JR, Tynan, A, et al. Survival as a Function of HbA1c In People With Type 2 Diabetes: A Retrospective Cohort Study. Lancet 2010;375:481-9.
Having followed an unconventional career path spanning some 25 years, Craig Currie has held appointments at five universities: Leicester, York, Dundee, Queensland and primarily in the School of Medicine at Cardiff University. Craig has also worked in industry in health outcomes, but for the last 11 years he has established and headed 2 research service companies. His current part-time, academic appointment is Reader in Diabetes Pharmacoepidemiology. The remainder of his time is spent servicing industry through his company, Pharmatelligence who carry out complex pharmacoeconomics and pharmacoepidemiology studies, and develop & manage disease registers. Craig and his team are particularly experienced in the use of routine health care data for the provision of health intelligence. Research into the economics and epidemiology of diabetes has been a long established hobby which has allowed for development of the necessary familiarity and confidence to now challenge some of the most vehemently held tenets in diabetes. The study related to this award represents a good example of this.

Ties Hoomans PhD, MSc Ties Hoomans PhD, MSc
Value of Information And Value Of Implementation: Application Of An Analytic Framework To Inform Resource Allocation Decisions In Metastatic Hormone-Refractory Prostate Cancer. Value Health 2009;12:315-24.

Ties Hoomans (PhD in Health Economics; MSc in Industrial Engineering and Management) is a Post Doctoral Research Fellow based in the Health Technology Assessment research program at the School for Public Health and Primary Care, Maastricht University, The Netherlands. He is also an associate member of the Health Economic Appraisals team at the University of Glasgow, United Kingdom. Hoomans was previously appointed as an advisor at the Dutch Health Care Insurance Board, and he conducted his PhD research on 'Economic evaluation of change in clinical practice' from 2004 till 2008.

Hoomans' research centres on the economic evaluation of health care technologies, with specific interest in implementation research and decision analysis. He has presented innovative methods for assessing the value of actively implementing evidence based care. Currently, his work concentrates on demonstrating the practicality of the methodology, while incorporating value of information methods. His research includes establishing more pragmatic applications of economic evaluations (e.g. risk sharing or coverage with evidence development schemes) and exploring the (potential) role of health economic information in decision making processes.

Maureen Rutten van Mölken Maureen Rutten van Mölken PhD
Associate Professor Health Economics
Institute for Medical Technology Assessment
Erasmus University/Erasmus Medical Centre, Rotterdam, The Netherlands

For the paper, Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPM. Expected Value of Perfect Information: An empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. Value in Health 2008;11:1070-80.

Maureen Rutten-van Mölken is an Associate Professor in Health Economics at the Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (IMTA/IBMG) of the Erasmus University/Erasmus Medical Centre in Rotterdam. She is vice-director of IMTA. She joint IMTA as a senior researcher in 1996. Before, she was an assistant professor in Health Economics and Medical Technology Assessment at the Department of Health Economics of the University of Maastricht. She was trained as a health scientist and had additional training in health economics and epidemiology. She obtained an MSc in health care policy and management at Maastricht University (1988), and a PhD in health economics, also at Maastricht University (1994). Her expertise includes economic evaluations alongside clinical trials as well as probabilistic decision analytic modeling of the cost-effectiveness of health care interventions, primarily in the area of respiratory diseases, smoking, rheumatology and several other chronic diseases. She has 20 years of experience in health economics and outcomes research and has been project leader of many applied economic evaluations and HTA-methodology studies leading to high level publications. She is a member of the committee "Implementation" of the Netherlands Organization for Health Research and Development (ZonMW), and a member of the scientific advisory board of the Dutch Asthma Foundation.

Greg Zaric PhD Greg Zaric PhD

For the paper, Zaric G, Brandeau ML. A little planning goes a long way: multilevel allocation of hiv prevention resources. Med Decis Making 2007;27:71-81.

Greg Zaric is an Associate Professor in the Management Science group at the Richard Ivey School of Business, as well as an Associate Professor of Epidemiology and Biostatistics at the Schulich School of Medicine and Dentistry, University of Western Ontario. His research focuses on applications of operations research and management science to problems in pharmacoeconomics, medical decision making, health care management and health economics. He currently holds a Canada Research Chair in Health Care Management Science. His publications have appeared in several journals including Journal of Health Economics, Management Science, Medical Decision Making, and Value in Health. He has PhD and MS degrees in Industrial Engineering from Stanford University and an M.ASc. from the University of Waterloo.

John Hsu, MD John Hsu, MD, MBA, MSCE
Physician Scientist
Kaiser Division of Research
Kaiser Institute for Health Policy

For the paper, Hsu J, Price M, Huang J, et al. Unintended Consequences of Caps on Medicare Drug Benefits. N Engl J Med 2006;354:2349-59.

John Hsu, MD, MBA, MSCE, is a Physician Scientist at the Kaiser Division of Research, Fellow at the Kaiser Institute for Health Policy, and Faculty at the University of California, San Francisco, Institute for Health Policy Studies and the Department of Epidemiology and Biostatistics. He received his MD and MSCE from the University of Pennsylvania School of Medicine, and his MBA from the Wharton School of Business.
Dr. Hsu studies changes in the financing and delivery of health care at the system level, with particular focus on the clinical and economic implications of these changes. He has ongoing NIH- and AHRQ-sponsored studies on the effects of patient cost-sharing for prescription drugs and medical care, and the impact of health information technology on prescribing for patients with chronic conditions. He has published extensively in journals including the New England Journal of Medicine, British Medical Journal, Health Services Research, and Medical Care.

Josephine A. Mauskopf Josephine A. Mauskopf PhD
Economics MHA, Health Administration
MA, Physiology/Pharmacology
Duke University

For the paper, Mauskopf J, Kitahatan, Kauf T, et al. HIV antiretrovial treatment: early versus later. J Acquir Immune Defic Syndr 2005;9:562-69.

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI Health Solutions. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomics research strategies and estimating budget impact and cost-effectiveness for new drugs for infectious diseases and psychiatric and neurologic illness. Dr. Mauskopf has used a broad range of decision analytic modeling techniques including decision tree analysis, Markov models, and discrete event simulation.
Dr Mauskopf is Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including the Journal of the American Medical Association, Journal of Acquired Immune Deficiency Syndrome, PharmacoEconomics, Medical Care, Value in Health, and Schizophrenia Bulletin.

Dr. SchneeweissDr. Schneeweiss

For the paper, Schneeweiss S, Dormuth C, Grootendorst P, et al. Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults: direct comparison of randomized and observational evaluations. Br Med J 2004:328:560-4.

Dr. Schneeweiss is Assistant Professor of Medicine and Epidemiology at Harvard Medical School. He is Director for Drug Evaluation and Outcomes Research in the Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital in Boston. He received an M.D. from the University of Munich and a Sc.D. degree in Epidemiology and Pharmaceutical Outcomes Research from Harvard.

He served on the faculty of the University of Munich Medical School before leading a research group in Boston. His current NIH-funded research focuses on clinical and economic consequences of drug reimbursement restrictions and the safety of pharmaceuticals and biotech products using large claims databases.

Dr. Schneeweiss has published in numerous scientific journals including the New England Journal of Medicine and is Fellow of the American College of Epidemiology and the International Society for Pharmacoepidemiology.

Josephine A. MauskopfEmily R. Cox, PhD
Director of Research
Office of Evidence Based Pharmacy Benefit Design
Express Scripts

For the paper, Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost-effectiveness of cyclooxygenase 2 inhibitors (COX-2s). Am J Manag Care 2003;9:785-94.

In her position as Director of Research, Dr. Cox conducts research related to the impact of plan benefit design on utilization of pharmaceuticals, geriatric pharmacoepidemiology, pharmacoeconomic evaluation of drug therapy, and geographic variation in the use of prescription drugs. She has published extensively, and her research has been funded by numerous organizations, including a grant by The Robert Wood Johnson Foundation evaluating the impact of capped prescription benefits on medication usage in Medicare populations. Previous to joining Express-Scripts, Dr Cox held joint positions in the Colleges of Pharmacy and Medicine at the University of Arizona where her research focused on prescription use in geriatric populations.

Jean-Michel Gaspoz MDJean-Michel Gaspoz MD
Clinique de Medecine II and the Division of Cardiology
Hopitaux Universitaires, Geneva, Switzerland

For the paper, "Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease." New England Journal of Medicine. 2003;348:562-3.

Jean-Michel Gaspoz, MD, MSc, trained in general internal medicine and in cardiology at the University Hospitals of Geneva, Switzerland, as well as at New England Deaconess Hospital and Brigham and Women's Hospital, Boston, USA.

He is a former fellow in Clinical effectiveness of the Division of Clinical Epidemiology of Brigham and Women's Hospital, Boston, and holds a Master of Science degree in Health Policy and Management from the Harvard School of Public Health, Boston, USA. Dr Gaspoz is Assistant Professor of Medicine at the University of Geneva Medical School, Geneva, Switzerland, Associate Physician-in-chief of the Clinique de Médecine 2 (Division of General Internal Medicine) and Senior Consultant at the Cardiology Division, Department of Medicine, Geneva University Hospitals. His research has focused on health

David W. Baker MD, MPHDavid W. Baker MD, MPH

For the paper, Baker DW, Sudano JJ, Abert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Eng J Med 2001;345:1106-12.

Dr. Baker is Associate Professor of Medicine and Epidemiology-Biostatistics at the Center for Health Care Research and Policy at MetroHealth Medical Center and Case Western Reserve University in Cleveland, Ohio. His research has focused on access to health care, health care delivery for vulnerable populations, and quality of care for patients with chronic medical conditions. Other areas of interest include the effect of limited reading ability and language barriers on patients' health care, and the cost-effectiveness of screening patients for early ventricular dysfunction. In addition to his research, he practices Internal Medicine and teaches at MetroHealth Medical Center.

Jean M. Mitchell PhDJean M. Mitchell PhD

For the paper, Mitchell JM, KH Anderson. Effects of case management and new drugs on medicaid aids spending. Health Affairs 2000;19:233-43.

Michael K. Gould MD, MSc Michael K. Gould MD, MSc

For the paper, Gould MK, Dembitzer AD, Doyle RL, et al. Low-milecular-weight hearins compared with unfractioned heparin for treatment of acute deep venous thrombosis. Ann Internal Med 1999;130:789-9.

Sean Sullivan PhDSean Sullivan PhD

For the paper, Mather DB, Sullivan SD, Augenstein D, et al. Evaluation clinical outcomes and economic consequences for formulary decision: a practical approach. Am J Manag Care 1999;5:277-85.

Deborah J. Partsch PharmDDeborah J. Partsch PharmD

For the paper, Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential of oflaxin versus standard switch therapy. Ann Pharmacother 1997;31:1137-45.

Nelda Johnson PharmDNelda Johnson PharmD

For the paper, Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilization in a us teaching hospital setting. Pharmacoeconomics 1993;31:471-81.

Awards Main Page